Jason M. Hafron, MD, discusses IsoPSA, a novel prostate-specific antigen assay for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
Jason M. Hafron, MD, CMO
Jason Hafron, MD, serves as the Chief Medical Officer at Michigan Institute of Urology.
Articles by Jason M. Hafron, MD, CMO
Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.
Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.
Latest Updated Articles
Hafron on IsoPSA: A Simpler, Smarter Tool for Prostate Cancer RiskPublished: May 2nd 2025 | Updated: